the experience of survival following blood and marrow transplant in nsw, australia
Post on 12-Apr-2017
276 Views
Preview:
TRANSCRIPT
Click icon to add picture
The experience of Survival following BMT in NSW
Gemma Dyer, MPH, GradCert Onc, BN, RN
eviQ Content Author and MPhil Student (Usyd)
3
Overview
› 1. Background› 2. The problem› 3. What we did› 4. What we found out › 5. Implications
BackgroundAllogeneic BMT…
4
Proportions of disease indications for an allogeneic HSCT in Europe in 2013
• Worldwide ~ 40,000• Australia = 495 (2013)• NSW = 173 (2013) (35%)
5
Background
Haematopoietic cell transplants by year and type
“The Problem”
oMalignant Disease:
• < 16yrs, 51 – 78%
• > 16yrs, 12 – 68%
oNon-malignant Disease:
• < 16yrs, 95%
• > 16yrs, 43-72%
Survival is improving
10-year Survival (ABMTRR 1998 - 2013)
6
“The problem” of survival post-BMT› Relapse (15-30%)› cGvHD (40-70%)› Cardio-respiratory disease (20-40%)› Endocrinopathies (>60%)› Infertility (Most)› Eye disease (>60%)› Osteoporosis (>40%)› Anxiety and depression, post-trauma› Social dysfunction› Isolation› Secondary cancers (2-8 x)
The problem of survival post-BMT› 59% risk of a chronic health condition by 10 years post BMT
› 3.5 x risk of a severe or life-threatening condition compared to siblings
› 30% lower life expectancy.
8
Aims1. Incidence and range of late complications 2. Health and functional status of survivors (not
causes of death)3. Address gaps in evidence-base: eg financial,
psychosocial, occupational, sexual function, fertility4. Identify gaps in service provision and create data
for advocacy5. Inform practice and patient education
Methods› Sampling frame
- Allogeneic transplant survivors, transplanted between Jan 1 2000 and Dec 31 2012 in NSW
› Instruments- Sydney Post BMT Survey (402 questions, 20 sections)
- FACT-BMT
- cGVHD Activity Assessment
- Lee Chronic GVHD symptom scale
- Post traumatic Growth Inventory
- Fear of Recurrence scale
- Depression, Anxiety & Stress Scale (DASS) 21
- Clinical data form (transplant procedure)
Validated instruments
n=1475Allogeneic BMT
2000-2012
n= 669Allogeneic BMT survivors
806 (55%)Deceased/status
unknown
n= 583 survivors (82.7%) contacted, sent survey
n= 443 survivors (66%)Returned Completed questionnaire
86 Unable to be contacted
17 (3%) declined consent123 surveys not returned
Results
asdasdDemographicsSVariable ResultsMedian survival 5 yrs (Range :1 yr 4 months- 22 yrs)
Median age at survey 54 yrs (Range :19 yrs-79 yrs)
Gender 252 (57%) maleCulture/ethnicity 324 (87%) Australian/European
Education Completed High School (23.6%)Completed University (39.1%)Trade/diploma/part high school (37.3%)
Annual Household income Low <$40,000 (36.5%)Middle $40- <$80,000 (29.2%)High >=$80,000 (34.3%)
Residential location 92% major city/inner regional; 8% outer regional/remote
Relationship status 71% married; 8% defacto21% single/separated/divorced
Results
13
Transplant details
14
Post BMT morbidity - cGvHD
15
Post BMT morbidity –chronic diseases
16
Post BMT morbidity – sexual dysfunction
FERTILITY/SEXUAL FUNCTION MALES Variable Decrease sexual enjoyment 45 (36.1%)Erectile dysfunction 99 (78.6%)Pain with Intercourse 12 (10.6%)Decreased libido 78 (61%)Difficulties with partner regarding sex 44 (37.3%)Any of the above 125 (93.3%)FEMALES Variable Decrease sexual enjoyment 76 (74.5%)Pain with Intercourse 73 (69.5%)Decreased libido 88 (82.2%)Difficulties with arousal 60 (60.6%)Difficulties with partner regarding sex ( 36 (37.5%)Any of the above 104 (89.7%)
17
Post BMT morbidity - infectionsInfection Result (n, %)
Recurrent colds 92 (22.8%)Influenza 161 (38.2%)Pertussis 11 (2.7%)Pneumococcal disease 21 (5.0%)Haemophilus influenzae type B 12 (2.9%)Tuberculosis 3 (0.7%)Hepatitis A 1 (0.24%)Hepatitis B 6 (1.4%)Hepatitis C 4 (0.9%)Varicella Zoster Infections Primary (Chicken Pox) Zoster/shingles
19 (4.5%)
118 (28%)
Measles 3 (0.7%)Mumps 2 (0.5%)Rubella 2 (0.5%)Pap smear abnormalities 18 (9.8%)Genital warts Male Female
12 (5.2%)3 (1.6%)
Meningococcal disease 0 (0%)Fungal infections Mucocutaneous (thrush/candida/skin)Aspergillosis/Lung/sinusOnychomycosis (nails)Invasive mycosis (prosthetic valve)Not specified
59 (14.4%)28 (6.9%)15 (3.6%)7 (1.7%)1 (0.2%)8 (1.9%)
Any vaccine preventable diseaseOn routine immunisation schedule(Pertussis, Haemophilus, Pneumoccus, Hep B, influenza)
184/443 (41.5%)
18
Post BMT morbidity – vaccination update
19
Post BMT morbidity – secondary cancers
› 24.1% reported a diagnosis of at least once cancer following BMT
› 21.2% skin cancer
› 1.6% oral cancers
› 4.4% other cancers - Bladder/prostate (4)
- Breast (2)
- Secondary haematological malignancy (3)
- PTLD (1)
- Bowel (1)
- Ovarian (1)
- Sarcoma (1)
- Not specified (4)
20
Post BMT social changes – household income
21
Post BMT social changes – employment status
22
Post BMT social changes – relationship status
› 39% relationship status remained unchanged
› 23% began a new relationship
› 43% divorced
23
Conclusions
› BMT survivors in NSW:- experience a high incidence and a broad range of physiological
and psycho-social complications- suffer from loss of employment, income and social reintegration
24
Implications
› This data should be used develop a Model of Care which is sustainable, cost-effective and consistent with patient needs:
- Long term follow up of BMT survivors is vital
- Dedicated MDT with include the BMT centre and survivors GP appears most suitable
- This in will hopefully lead to:
- Reduced morbidity and mortality related to BMT survival
- Improved Quality of Life post BMT
Acknowledgements› Agency for Clinical Innovation BMT Network › BMT Physicians, Researchers, Data Managers, BMT CNCs at each site: › Primary Research Team: Lisa Brice, Nicky Gilroy, Masura Kabir, Ian
Kerridge› RNS: Matthew Greenwood, Kelly Wong, Julian Lindsay, Jennifer Smith,
Chris Poon, Grace Gifford› StVH: John Moore, Jeff Tan, Karim Ibrahim,› RPA: Stephen Larsen, Ann-Marie Johnston, Paris Manii› Westmead: John Kwan, Mark Hertzberg, Megan Hogg, Gillian Huang,
Mark Schifter› Newcastle: Louisa Brown› Patients
25
top related